Varenicline — the medication with the strongest evidence base for nicotine cessation — is now available as an affordable generic. And you no longer need a doctor's appointment to get it.
If you've heard of Chantix, you probably heard it was expensive, hard to get, or came with scary warnings. Most of that is outdated. Here's the current reality, and how to access varenicline quickly and affordably in 2026.
Pfizer's brand-name Chantix was voluntarily recalled in 2021 due to contamination issues at a third-party manufacturer. For nearly two years, varenicline was essentially unavailable in the US.
In 2023, generic varenicline returned to the market: same active ingredient, same mechanism, same clinical results, dramatically lower price. Where brand-name Chantix once cost $500-600/month without insurance, generic varenicline is now a fraction of that. Most people still don't know it's back. That's the gap.
FDA-approved since 2006. Black box warning removed in 2016 after the landmark EAGLES trial. Added to the WHO Essential Medicines list in 2021. Nearly 20 years of clinical evidence. This is the standard of care.
The appointment barrier. Getting a prescription traditionally meant scheduling a primary care visit: weeks of waiting, time off work, a co-pay. A lot of people who genuinely want to quit never make it through that friction.
The Chantix reputation. Years of black-box warning headlines left many people with the impression that varenicline is dangerous. The warning was removed in 2016. The medication is safe and well-studied.
Cost confusion. Many people still think Chantix pricing means $500+/month, without knowing that generic varenicline exists and costs far less.
"The medication exists. The evidence is overwhelming. The only barrier left is access — and telehealth has removed it."
Varenicline has been prescribed to over 20 million people worldwide. The safety profile is well-characterized after nearly two decades of clinical use.
Nausea is the most frequently reported side effect, occurring in about 30% of patients during the first weeks. Most cases are mild to moderate and resolve as the body adjusts. Taking varenicline with food and a full glass of water reduces nausea significantly. Vivid dreams or sleep disturbance affect roughly 15% of patients in the first month. They typically fade after the dosing ramp completes. Headache and constipation are reported less frequently and usually resolve on their own.
From 2009 to 2016, varenicline carried an FDA black box warning about neuropsychiatric side effects, including mood changes and suicidal ideation. The warning was based on post-marketing reports, not controlled trials.
The EAGLES trial, published in 2016 in The Lancet, was the largest smoking cessation trial ever conducted. It enrolled over 8,000 patients including a large psychiatric cohort and directly compared varenicline against bupropion, nicotine patches, and placebo. The trial found no significant increase in neuropsychiatric adverse events with varenicline compared to placebo, even among patients with a history of psychiatric conditions. The FDA removed the black box warning in December 2016.
Varenicline is not appropriate for people with severe kidney impairment without dose adjustment, anyone with a known hypersensitivity to varenicline, or individuals who are pregnant or breastfeeding. Patients with a history of seizures, cardiovascular disease, or active psychiatric illness should disclose those conditions during intake. The reviewing physician will determine appropriateness on a case-by-case basis.
This is the question most people ask first, and the answer has changed dramatically since 2023.
Brand-name Chantix at retail pharmacies historically ran $485 to $620 per month without insurance, depending on the pharmacy. Generic varenicline at major retail chains typically ranges from $60 to $180 per month with discount programs like GoodRx. Through telehealth platforms that fulfill directly, the cost is often lower because there's no retail markup layer.
One-time consultation: $75, backed by our satisfaction guarantee — refunded in full if our physician recommends against varenicline and you'd prefer not to explore alternatives. Monthly medication: $150, including dispensing and shipping. The 12-week protocol totals $525 all-in. There are no hidden fees, no insurance billing, and no surprise charges.
Varenicline is a prescription medication for a recognized medical condition (nicotine dependence, ICD-10 code F17). Both the consultation fee and the medication itself are HSA and FSA eligible under IRS rules. You'll receive an itemized receipt suitable for HSA/FSA reimbursement.
Many commercial insurance plans cover generic varenicline with a low copay. Medicare Part D plans cover it under most formularies. If you have insurance and prefer to use it, you can fill a Respiro prescription at your local pharmacy of choice instead of through our fulfillment partner. The $75 consultation fee remains the same either way.
Five FDA-approved options exist for nicotine cessation. Here's how they compare on efficacy, mechanism, and practical fit.
NRT works by replacing nicotine at lower, declining doses. It's available over-the-counter and is generally safe. The 12-week abstinence rate is roughly 16%, compared to 44% for varenicline. NRT is a reasonable starting point for light users or anyone who wants to avoid prescription medications. For moderate to heavy users, the evidence strongly favors varenicline.
Bupropion is an antidepressant that also reduces nicotine cravings. The 12-week abstinence rate is approximately 22%, roughly half of varenicline's. Bupropion is a reasonable choice for patients who can't take varenicline, or for those who would also benefit from antidepressant effects. The EAGLES trial directly compared the two and varenicline outperformed bupropion across every subgroup measured.
Cytisine is a similar partial agonist available in some countries but not yet FDA-approved in the US as of 2026. Head-to-head trials have shown comparable efficacy with a slightly different side effect profile. For US patients, varenicline remains the best-evidenced option.
Unassisted quit attempts have a 12-week success rate of 3 to 5%. The willpower-only approach works for some people, but the math is unkind: most people who try it relapse within a month. Varenicline addresses the neurobiology of nicotine dependence directly, which is why it works.
Respiro is designed to serve adults 18 and older across a planned 50-state launch who use nicotine and want to quit. The intake collects health history, current medications, and a brief mental health screen. A licensed physician reviews the information and decides whether varenicline is appropriate.
Adults with no significant kidney disease, no history of recent seizures, no active suicidal ideation, no allergy to varenicline, and not currently pregnant or breastfeeding. The vast majority of adults who use nicotine and want to quit fall into this group.
Patients with a history of psychiatric conditions, cardiovascular disease, or kidney impairment can often still receive varenicline, but the reviewing physician may request additional information or recommend a different approach. Under our satisfaction guarantee, the $75 consultation fee is refunded in full if our physician recommends against varenicline and you'd prefer not to explore alternatives.
Varenicline follows a structured 12-week protocol with a one-week dose ramp. Here's what the timeline looks like.
Days 1 to 3 you take 0.5 mg once daily. Days 4 to 7 you take 0.5 mg twice daily. You're still using nicotine during this week. Your quit date is set for day 8 to day 14: most patients pick day 8.
From day 8 onward you take 1 mg twice daily. This is when most patients notice that cigarettes, vapes, or pouches stop being satisfying. The pleasure response is blunted by the partial agonist mechanism. Cravings remain but are noticeably easier to ride out.
Most patients who will succeed on varenicline are nicotine-free by week 4. If you're still using at this point, that's useful information for your physician. Sometimes the protocol is extended or the dose is adjusted.
The standard course is 12 weeks. For patients with high relapse risk, the FDA label allows an additional 12-week course to lock in abstinence. Approximately 44% of patients who complete the full course remain abstinent at 12 weeks. Long-term abstinence rates at one year are roughly 25 to 30%, which is several times higher than any other approach.
Yes. Generic varenicline contains the identical active ingredient at the same strengths (0.5 mg and 1 mg) as brand-name Chantix. The FDA requires generic medications to demonstrate bioequivalence to the brand-name product. Clinical results, side effect profile, and dosing are the same.
The intake form takes about 10 minutes to complete. A licensed physician reviews your submission, typically within 24 hours. If approved, your prescription is sent to fulfillment the same day and ships in 3 to 5 business days. Total time from start to receiving medication is usually under one week.
No. Respiro uses an asynchronous review model. The physician reviews your written intake on their schedule. There's no scheduled appointment, no video call, and no waiting room. If the physician needs additional information, they'll request it through the platform.
Yes. Varenicline works on the same nicotinic receptors regardless of how nicotine is delivered. Clinical evidence is strongest for cigarettes (the population studied in trials), but the mechanism applies to vapes, pouches, dip, and other forms of nicotine use. Many Respiro patients use varenicline to quit vaping or pouches.
The reviewing physician may recommend against varenicline based on your health history — and may suggest an alternative such as bupropion if it's a better clinical fit. Under our satisfaction guarantee, if you'd prefer not to explore alternatives, your $75 consultation fee is refunded in full.
If our physician reviews your case and recommends against varenicline — and you'd prefer not to explore alternatives like bupropion — your $75 consultation fee is refunded in full. No partial refund, no processing fee.
Varenicline and the consultation fee are HSA and FSA eligible because nicotine dependence is a recognized medical condition (ICD-10 code F17). You'll receive an itemized receipt suitable for reimbursement. We recommend confirming acceptance with your specific plan administrator.
Most patients complete the standard 12-week course and are abstinent. For patients with high relapse risk, the FDA label allows an additional 12-week course. Your physician can extend treatment if clinically appropriate. There's no auto-renewal — refills require physician approval.
No. Varenicline is not a controlled substance. It works as a partial agonist at nicotinic receptors, which means it doesn't produce the reward response that nicotine does. There's no dependence potential and no withdrawal when stopping the medication.
The FDA label notes that varenicline may alter alcohol tolerance for some patients, including reduced alcohol tolerance and rare reports of unusual behavior while drinking. Most patients can drink moderately without issues, but it's worth being conservative during the first weeks while your body adjusts. Discuss specifics with your reviewing physician if you have concerns.
Respiro is a direct-to-consumer telehealth platform built around nicotine cessation. $75 one-time consultation fee — backed by our satisfaction guarantee. $150/month for your varenicline prescription, fulfilled and shipped to you. Async only. Planned 50-state launch. Real physicians, real clinical process.
$75 consultation. Physician review within 24 hours. Varenicline shipped to your door. $75 consultation, satisfaction guaranteed.
Get Early Access in 60 Seconds →